Report cover image

Global Anti-Obesity Prescription Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 193 Pages
SKU # APRC20560993

Description

Summary

According to APO Research, The global Anti-Obesity Prescription market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Anti-Obesity Prescription is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Anti-Obesity Prescription is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Anti-Obesity Prescription is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Anti-Obesity Prescription is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Anti-Obesity Prescription include Akrimax Pharmaceuticals, Alpex Pharma, Arena Pharmaceuticals, Arrowhead Research, Bridge BioResearch, Compellis Pharmaceuticals, Yungjin Pharm, Zealand Pharma and Zydus Cadila, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Anti-Obesity Prescription, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Anti-Obesity Prescription, also provides the sales of main regions and countries. Of the upcoming market potential for Anti-Obesity Prescription, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anti-Obesity Prescription sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Anti-Obesity Prescription market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Anti-Obesity Prescription sales, projected growth trends, production technology, application and end-user industry.

Anti-Obesity Prescription Segment by Company

Akrimax Pharmaceuticals
Alpex Pharma
Arena Pharmaceuticals
Arrowhead Research
Bridge BioResearch
Compellis Pharmaceuticals
Yungjin Pharm
Zealand Pharma
Zydus Cadila
Anti-Obesity Prescription Segment by Type

Lorcaserin
Liraglutide
Phentermine and Topiramate
Orlistat
Bupropion and Naltrexone
Anti-Obesity Prescription Segment by Application

E-Commerce
Retail Pharmacies
Hospital Pharmacies
Anti-Obesity Prescription Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Obesity Prescription market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Obesity Prescription and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Obesity Prescription.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Anti-Obesity Prescription in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Anti-Obesity Prescription manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-Obesity Prescription sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

193 Pages
1 Market Overview
1.1 Product Definition
1.2 Anti-Obesity Prescription Market by Type
1.2.1 Global Anti-Obesity Prescription Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Lorcaserin
1.2.3 Liraglutide
1.2.4 Phentermine and Topiramate
1.2.5 Orlistat
1.2.6 Bupropion and Naltrexone
1.3 Anti-Obesity Prescription Market by Application
1.3.1 Global Anti-Obesity Prescription Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 E-Commerce
1.3.3 Retail Pharmacies
1.3.4 Hospital Pharmacies
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Anti-Obesity Prescription Market Dynamics
2.1 Anti-Obesity Prescription Industry Trends
2.2 Anti-Obesity Prescription Industry Drivers
2.3 Anti-Obesity Prescription Industry Opportunities and Challenges
2.4 Anti-Obesity Prescription Industry Restraints
3 Global Market Growth Prospects
3.1 Global Anti-Obesity Prescription Revenue Estimates and Forecasts (2020-2031)
3.2 Global Anti-Obesity Prescription Revenue by Region
3.2.1 Global Anti-Obesity Prescription Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Anti-Obesity Prescription Revenue by Region (2020-2025)
3.2.3 Global Anti-Obesity Prescription Revenue by Region (2026-2031)
3.2.4 Global Anti-Obesity Prescription Revenue Market Share by Region (2020-2031)
3.3 Global Anti-Obesity Prescription Sales Estimates and Forecasts 2020-2031
3.4 Global Anti-Obesity Prescription Sales by Region
3.4.1 Global Anti-Obesity Prescription Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Anti-Obesity Prescription Sales by Region (2020-2025)
3.4.3 Global Anti-Obesity Prescription Sales by Region (2026-2031)
3.4.4 Global Anti-Obesity Prescription Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Anti-Obesity Prescription Revenue by Manufacturers
4.1.1 Global Anti-Obesity Prescription Revenue by Manufacturers (2020-2025)
4.1.2 Global Anti-Obesity Prescription Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Anti-Obesity Prescription Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Anti-Obesity Prescription Sales by Manufacturers
4.2.1 Global Anti-Obesity Prescription Sales by Manufacturers (2020-2025)
4.2.2 Global Anti-Obesity Prescription Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Anti-Obesity Prescription Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Anti-Obesity Prescription Sales Price by Manufacturers (2020-2025)
4.4 Global Anti-Obesity Prescription Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Anti-Obesity Prescription Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Anti-Obesity Prescription Manufacturers, Product Type & Application
4.7 Global Anti-Obesity Prescription Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Anti-Obesity Prescription Market CR5 and HHI
4.8.2 2024 Anti-Obesity Prescription Tier 1, Tier 2, and Tier 3
5 Anti-Obesity Prescription Market by Type
5.1 Global Anti-Obesity Prescription Revenue by Type
5.1.1 Global Anti-Obesity Prescription Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Anti-Obesity Prescription Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Anti-Obesity Prescription Revenue Market Share by Type (2020-2031)
5.2 Global Anti-Obesity Prescription Sales by Type
5.2.1 Global Anti-Obesity Prescription Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Anti-Obesity Prescription Sales by Type (2020-2031) & (k units)
5.2.3 Global Anti-Obesity Prescription Sales Market Share by Type (2020-2031)
5.3 Global Anti-Obesity Prescription Price by Type
6 Anti-Obesity Prescription Market by Application
6.1 Global Anti-Obesity Prescription Revenue by Application
6.1.1 Global Anti-Obesity Prescription Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Anti-Obesity Prescription Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Anti-Obesity Prescription Revenue Market Share by Application (2020-2031)
6.2 Global Anti-Obesity Prescription Sales by Application
6.2.1 Global Anti-Obesity Prescription Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Anti-Obesity Prescription Sales by Application (2020-2031) & (k units)
6.2.3 Global Anti-Obesity Prescription Sales Market Share by Application (2020-2031)
6.3 Global Anti-Obesity Prescription Price by Application
7 Company Profiles
7.1 Akrimax Pharmaceuticals
7.1.1 Akrimax Pharmaceuticals Comapny Information
7.1.2 Akrimax Pharmaceuticals Business Overview
7.1.3 Akrimax Pharmaceuticals Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Akrimax Pharmaceuticals Anti-Obesity Prescription Product Portfolio
7.1.5 Akrimax Pharmaceuticals Recent Developments
7.2 Alpex Pharma
7.2.1 Alpex Pharma Comapny Information
7.2.2 Alpex Pharma Business Overview
7.2.3 Alpex Pharma Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Alpex Pharma Anti-Obesity Prescription Product Portfolio
7.2.5 Alpex Pharma Recent Developments
7.3 Arena Pharmaceuticals
7.3.1 Arena Pharmaceuticals Comapny Information
7.3.2 Arena Pharmaceuticals Business Overview
7.3.3 Arena Pharmaceuticals Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Arena Pharmaceuticals Anti-Obesity Prescription Product Portfolio
7.3.5 Arena Pharmaceuticals Recent Developments
7.4 Arrowhead Research
7.4.1 Arrowhead Research Comapny Information
7.4.2 Arrowhead Research Business Overview
7.4.3 Arrowhead Research Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Arrowhead Research Anti-Obesity Prescription Product Portfolio
7.4.5 Arrowhead Research Recent Developments
7.5 Bridge BioResearch
7.5.1 Bridge BioResearch Comapny Information
7.5.2 Bridge BioResearch Business Overview
7.5.3 Bridge BioResearch Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Bridge BioResearch Anti-Obesity Prescription Product Portfolio
7.5.5 Bridge BioResearch Recent Developments
7.6 Compellis Pharmaceuticals
7.6.1 Compellis Pharmaceuticals Comapny Information
7.6.2 Compellis Pharmaceuticals Business Overview
7.6.3 Compellis Pharmaceuticals Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Compellis Pharmaceuticals Anti-Obesity Prescription Product Portfolio
7.6.5 Compellis Pharmaceuticals Recent Developments
7.7 Yungjin Pharm
7.7.1 Yungjin Pharm Comapny Information
7.7.2 Yungjin Pharm Business Overview
7.7.3 Yungjin Pharm Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Yungjin Pharm Anti-Obesity Prescription Product Portfolio
7.7.5 Yungjin Pharm Recent Developments
7.8 Zealand Pharma
7.8.1 Zealand Pharma Comapny Information
7.8.2 Zealand Pharma Business Overview
7.8.3 Zealand Pharma Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Zealand Pharma Anti-Obesity Prescription Product Portfolio
7.8.5 Zealand Pharma Recent Developments
7.9 Zydus Cadila
7.9.1 Zydus Cadila Comapny Information
7.9.2 Zydus Cadila Business Overview
7.9.3 Zydus Cadila Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Zydus Cadila Anti-Obesity Prescription Product Portfolio
7.9.5 Zydus Cadila Recent Developments
8 North America
8.1 North America Anti-Obesity Prescription Market Size by Type
8.1.1 North America Anti-Obesity Prescription Revenue by Type (2020-2031)
8.1.2 North America Anti-Obesity Prescription Sales by Type (2020-2031)
8.1.3 North America Anti-Obesity Prescription Price by Type (2020-2031)
8.2 North America Anti-Obesity Prescription Market Size by Application
8.2.1 North America Anti-Obesity Prescription Revenue by Application (2020-2031)
8.2.2 North America Anti-Obesity Prescription Sales by Application (2020-2031)
8.2.3 North America Anti-Obesity Prescription Price by Application (2020-2031)
8.3 North America Anti-Obesity Prescription Market Size by Country
8.3.1 North America Anti-Obesity Prescription Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Anti-Obesity Prescription Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Anti-Obesity Prescription Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
9 Europe
9.1 Europe Anti-Obesity Prescription Market Size by Type
9.1.1 Europe Anti-Obesity Prescription Revenue by Type (2020-2031)
9.1.2 Europe Anti-Obesity Prescription Sales by Type (2020-2031)
9.1.3 Europe Anti-Obesity Prescription Price by Type (2020-2031)
9.2 Europe Anti-Obesity Prescription Market Size by Application
9.2.1 Europe Anti-Obesity Prescription Revenue by Application (2020-2031)
9.2.2 Europe Anti-Obesity Prescription Sales by Application (2020-2031)
9.2.3 Europe Anti-Obesity Prescription Price by Application (2020-2031)
9.3 Europe Anti-Obesity Prescription Market Size by Country
9.3.1 Europe Anti-Obesity Prescription Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Anti-Obesity Prescription Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Anti-Obesity Prescription Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Netherlands
9.3.9 Nordic Countries
10 China
10.1 China Anti-Obesity Prescription Market Size by Type
10.1.1 China Anti-Obesity Prescription Revenue by Type (2020-2031)
10.1.2 China Anti-Obesity Prescription Sales by Type (2020-2031)
10.1.3 China Anti-Obesity Prescription Price by Type (2020-2031)
10.2 China Anti-Obesity Prescription Market Size by Application
10.2.1 China Anti-Obesity Prescription Revenue by Application (2020-2031)
10.2.2 China Anti-Obesity Prescription Sales by Application (2020-2031)
10.2.3 China Anti-Obesity Prescription Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Anti-Obesity Prescription Market Size by Type
11.1.1 Asia Anti-Obesity Prescription Revenue by Type (2020-2031)
11.1.2 Asia Anti-Obesity Prescription Sales by Type (2020-2031)
11.1.3 Asia Anti-Obesity Prescription Price by Type (2020-2031)
11.2 Asia Anti-Obesity Prescription Market Size by Application
11.2.1 Asia Anti-Obesity Prescription Revenue by Application (2020-2031)
11.2.2 Asia Anti-Obesity Prescription Sales by Application (2020-2031)
11.2.3 Asia Anti-Obesity Prescription Price by Application (2020-2031)
11.3 Asia Anti-Obesity Prescription Market Size by Country
11.3.1 Asia Anti-Obesity Prescription Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Anti-Obesity Prescription Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Anti-Obesity Prescription Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Anti-Obesity Prescription Market Size by Type
12.1.1 SAMEA Anti-Obesity Prescription Revenue by Type (2020-2031)
12.1.2 SAMEA Anti-Obesity Prescription Sales by Type (2020-2031)
12.1.3 SAMEA Anti-Obesity Prescription Price by Type (2020-2031)
12.2 SAMEA Anti-Obesity Prescription Market Size by Application
12.2.1 SAMEA Anti-Obesity Prescription Revenue by Application (2020-2031)
12.2.2 SAMEA Anti-Obesity Prescription Sales by Application (2020-2031)
12.2.3 SAMEA Anti-Obesity Prescription Price by Application (2020-2031)
12.3 SAMEA Anti-Obesity Prescription Market Size by Country
12.3.1 SAMEA Anti-Obesity Prescription Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Anti-Obesity Prescription Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Anti-Obesity Prescription Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Anti-Obesity Prescription Value Chain Analysis
13.1.1 Anti-Obesity Prescription Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Anti-Obesity Prescription Production Mode & Process
13.2 Anti-Obesity Prescription Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Anti-Obesity Prescription Distributors
13.2.3 Anti-Obesity Prescription Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.